Study to Investigate the Effect of Deferasirox on the Pharmacokinetics of Midazolam

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This is a study to investigate the pharmacokinetics of deferasirox

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Novartis
• Treatments: Deferasirox; Midazolam

Criteria

Inclusion Criteria:

• Good health

• No evidence of iron deficiency

• Weight between 50 and 100 kg

• Body Mass Index between 19 and 29 kg/m2

Exclusion Criteria:

• Use of certain drugs, herbal remedies or nutrients

Other protocol-defined inclusion/exclusion criteria may apply